Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Payables: 2013-2024

Historic Payables for Fortress Biotech (FBIO) over the last 12 years, with Dec 2024 value amounting to $65.5 million.

  • Fortress Biotech's Payables fell 29.97% to $45.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.5 million, marking a year-over-year decrease of 20.41%. This contributed to the annual value of $65.5 million for FY2024, which is 10.96% down from last year.
  • Fortress Biotech's Payables amounted to $65.5 million in FY2024, which was down 10.96% from $73.6 million recorded in FY2023.
  • In the past 5 years, Fortress Biotech's Payables ranged from a high of $100.4 million in FY2022 and a low of $45.4 million during FY2020.
  • Its 3-year average for Payables is $79.8 million, with a median of $73.6 million in 2023.
  • Its Payables has fluctuated over the past 5 years, first surged by 101.53% in 2021, then declined by 26.73% in 2023.
  • Fortress Biotech's Payables (Yearly) stood at $45.4 million in 2020, then skyrocketed by 101.53% to $91.5 million in 2021, then climbed by 9.75% to $100.4 million in 2022, then declined by 26.73% to $73.6 million in 2023, then declined by 10.96% to $65.5 million in 2024.